Date: 2011-04-07
Type of information: Development agreement
Compound: undisclosed peptide
Company: OctoPlus (The Netherlands) one of top 10 biopharmaceutical company
Therapeutic area: undisclosed
Type agreement: development
Action mechanism:
Disease: undisclosed
Details: OctoPlus has signed a feasibility agreement with a top-10 biopharmaceutical company to develop a controlled release formulation.Under the contract announced today, OctoPlus will develop a controlled release formulation of an undisclosed peptide compound. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Financial terms: Financial terms of the current agreement are not disclosed.
Latest news:
